These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 403541)

  • 1. Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.
    Gerlach J
    Psychopharmacology (Berl); 1977 Mar; 51(3):259-63. PubMed ID: 403541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between parkinsonism and tardive dyskinesia.
    Gerlach J
    Am J Psychiatry; 1977 Jul; 134(7):781-4. PubMed ID: 869056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of two iatrogenic dyskinesias.
    Karson CN; Jeste DV; LeWitt PA; Wyatt RJ
    Am J Psychiatry; 1983 Nov; 140(11):1504-6. PubMed ID: 6137963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Bathien N; Rondot P; Koutlidis RM
    J Physiol (Paris); 1981 Apr; 77(1):131-41. PubMed ID: 6112268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyskinesia: L-dopa-induced and tardive dyskinesia.
    Rascol O; Fabre N
    Clin Neuropharmacol; 2001; 24(6):313-23. PubMed ID: 11801806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative study of levodopa-induced dyskinesia in Parkinson's disease.
    Caligiuri MP; Peterson S
    J Neural Transm Park Dis Dement Sect; 1993; 6(2):89-98. PubMed ID: 8117413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Abnormal movements induced by psychotropic drugs].
    Rondot P; Bathien N
    Encephale; 1979; 5(1):41-8. PubMed ID: 477589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unilateral Parkinson's disease and contralateral tardive dyskinesia: a unique case with successful therapy that may explain the pathophysiology of these two disorders.
    Fahn S; Mayeux R
    J Neural Transm Suppl; 1980; (16):179-85. PubMed ID: 6933220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
    Miller R; Chouinard G
    Biol Psychiatry; 1993 Nov; 34(10):713-38. PubMed ID: 7904833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment.
    Gerlach J; Thorsen K
    Int Pharmacopsychiatry; 1976; 11(1):1-7. PubMed ID: 770362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [L-dopa induced dyskinesia in Parkinson's disease].
    Bastide MF; Bézard E
    Bull Acad Natl Med; 2015; 199(2-3):201-12. PubMed ID: 27476302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease.
    Guridi J; Obeso JA; Rodriguez-Oroz MC; Lozano AA; Manrique M
    Neurosurgery; 2008 Feb; 62(2):311-23; discussion 323-5. PubMed ID: 18382309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
    Cenci MA
    Trends Neurosci; 2007 May; 30(5):236-43. PubMed ID: 17400300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.